Wednesday, March 13, 2024 1:45:21 PM
Might be why you found information about them as being in England. They are owned by a company from England. But still no way to know if Lisa really gave them an interview... Jaguar will not comment on it... they will only comment on what is already been made public but who I talked to would not comment on any news article he does not have direct knowledge of.... I gave him my contact info and asked if someone could call me back... I will pass it on was his reply.
jaguar phone 415 371 8300
I doubt he moved from his chair or called anyone.
https://www.pharmaceutical-technology.com/editorial-standards/#:~:text=We%20are%20headquartered%20in%20London%20and%20part,and%20comment%20is%20provided%20by%20industry%20experts
Editorial Standards
The Verdict network of websites uphold the highest standards of ethical and professional journalism.
The quality and trustworthiness of the information we provide to readers is fundamental to the success of our business.
In our news coverage we seek to be independent, fair and accurate.
We are headquartered in London and part of business intelligence company GlobalData plc.
Much of our analysis and comment is provided by industry experts working for GlobalData. Any comment is clearly labelled as such.
Our mission is to provide a news and information service which helps our readers to make better decisions for themselves, their businesses and the world.
Our editorial focus is global, but as we are headquartered in London our house style is to generally use UK English spelling and grammar.
We make every effort to verify and check the information we publish. If you spot a mistake, or would like to make a complaint about our coverage, please contact editorialenquiries@globaldata.com. All mistakes will be corrected as soon as possible.
Advertising
Any content paid for by an advertiser is clearly labelled as such using words such as “sponsored”, “advertising” or “advertorial”. Content which is editorially independent but created with the help of specific funding from an advertiser may be presented with the words “in association with” or “supported by”.
Attribution
Information that has not been independently verified should be attributed to the source it has been taken from. Quotes which we have not gathered ourselves should be attributed to a source.
Plagiarism
It is forbidden for our journalists to copy information from other sources without attribution.
IPSO Editors’ Code
Verdict’s journalists are required to follow the standards laid out in the UK Editors’ Code with specific attention to the clauses on Financial Journalism:
Journalists must not use for their own profit financial information they receive in advance of its general publication, nor should they pass such information to others
They must not write about shares or securities in whose performance they know that they or their close families have a significant financial interest without disclosing the interest to the editor or financial editor.
They must not buy or sell, either directly or through nominees or agents, shares or securities about which they have written recently or about which they intend to write in the near future.
Sources
Stories are never sent to sources in advance of publication. Journalists may however choose to provide a copy of direct quotes with a source in advance of publication to check for accuracy.
Named sources are preferable to anonymous ones, but there may be occasions where we publish information from unnamed sources, provided we are satisfied that they have a good reason to remain anonymous and are providing us with high-quality information.
Our journalists have a duty to protect confidential sources.
PharmaceuticalTechnology
The leading site for news and procurement in the pharmaceutical industry
jaguar phone 415 371 8300
I doubt he moved from his chair or called anyone.
https://www.pharmaceutical-technology.com/editorial-standards/#:~:text=We%20are%20headquartered%20in%20London%20and%20part,and%20comment%20is%20provided%20by%20industry%20experts
Editorial Standards
The Verdict network of websites uphold the highest standards of ethical and professional journalism.
The quality and trustworthiness of the information we provide to readers is fundamental to the success of our business.
In our news coverage we seek to be independent, fair and accurate.
We are headquartered in London and part of business intelligence company GlobalData plc.
Much of our analysis and comment is provided by industry experts working for GlobalData. Any comment is clearly labelled as such.
Our mission is to provide a news and information service which helps our readers to make better decisions for themselves, their businesses and the world.
Our editorial focus is global, but as we are headquartered in London our house style is to generally use UK English spelling and grammar.
We make every effort to verify and check the information we publish. If you spot a mistake, or would like to make a complaint about our coverage, please contact editorialenquiries@globaldata.com. All mistakes will be corrected as soon as possible.
Advertising
Any content paid for by an advertiser is clearly labelled as such using words such as “sponsored”, “advertising” or “advertorial”. Content which is editorially independent but created with the help of specific funding from an advertiser may be presented with the words “in association with” or “supported by”.
Attribution
Information that has not been independently verified should be attributed to the source it has been taken from. Quotes which we have not gathered ourselves should be attributed to a source.
Plagiarism
It is forbidden for our journalists to copy information from other sources without attribution.
IPSO Editors’ Code
Verdict’s journalists are required to follow the standards laid out in the UK Editors’ Code with specific attention to the clauses on Financial Journalism:
Journalists must not use for their own profit financial information they receive in advance of its general publication, nor should they pass such information to others
They must not write about shares or securities in whose performance they know that they or their close families have a significant financial interest without disclosing the interest to the editor or financial editor.
They must not buy or sell, either directly or through nominees or agents, shares or securities about which they have written recently or about which they intend to write in the near future.
Sources
Stories are never sent to sources in advance of publication. Journalists may however choose to provide a copy of direct quotes with a source in advance of publication to check for accuracy.
Named sources are preferable to anonymous ones, but there may be occasions where we publish information from unnamed sources, provided we are satisfied that they have a good reason to remain anonymous and are providing us with high-quality information.
Our journalists have a duty to protect confidential sources.
PharmaceuticalTechnology
The leading site for news and procurement in the pharmaceutical industry
Recent JAGX News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/27/2026 01:10:06 PM
- Jaguar Health Compliant with Nasdaq Bid Price Rule • ACCESS Newswire • 05/27/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 09:22:44 PM
- Jaguar Health Reports First Quarter 2026 Financials • ACCESS Newswire • 05/20/2026 08:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:36:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/20/2026 08:06:56 PM
- Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference • ACCESS Newswire • 05/20/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/19/2026 09:07:21 PM
- Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer • ACCESS Newswire • 05/19/2026 01:00:00 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/18/2026 07:06:14 PM
- Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule • ACCESS Newswire • 05/08/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 06:59:08 PM
- Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID) • ACCESS Newswire • 05/06/2026 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2026 12:00:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 09:09:41 PM
- Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 12:00:18 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 01:57:16 PM
- Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs • ACCESS Newswire • 04/29/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/27/2026 01:10:06 PM
- Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split • ACCESS Newswire • 04/27/2026 01:00:00 PM
- Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN) • ACCESS Newswire • 04/24/2026 12:30:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/21/2026 12:22:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/21/2026 11:35:12 AM
- Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders • ACCESS Newswire • 04/20/2026 08:15:00 PM

